BSE: 543524 | NSE: RAINBOW | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Rainbow Childrens Medicare Ltd is a good quality company.
The key valuation ratios of Rainbow Childrens Medicare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Rainbow Childrens Medicare Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 0% | 0% | 12.9% | 14.4% | 20.3% | 32.9% | 21.9% | 40.5% | 37.2% | 29.4% | - |
| Value Creation Index ⓘ | NA | NA | 0.0 | 0.1 | 0.5 | 1.4 | 0.6 | 1.9 | 1.8 | 1.2 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 0 | 0 | 321 | 402 | 543 | 695 | 614 | 925 | 1,114 | 1,237 | 1,366 |
| Sales YoY Gr. | - | NA | NA | 25.1% | 35.1% | 28.1% | -11.6% | 50.5% | 20.5% | 11% | - |
| Adj EPS ⓘ | 0 | 0 | 3.5 | 4 | 6.6 | 7.9 | 5.5 | 15.1 | 20.6 | 21.2 | 22.4 |
| YoY Gr. | - | NA | NA | 15.2% | 64.8% | 18.9% | -30.3% | 175% | 36.8% | 2.7% | - |
| BVPS (₹) ⓘ | 0 | 0 | 34.9 | 38.7 | 44.7 | 46 | 51.6 | 66.5 | 107.2 | 125.7 | 134.7 |
| Adj Net Profit ⓘ | 0 | 0 | 31.4 | 36.1 | 59.6 | 70.9 | 49.4 | 142 | 209 | 215 | 228 |
| Cash Flow from Ops. ⓘ | 0 | 0 | 35.6 | 47.9 | 95.9 | 178 | 142 | 214 | 316 | 306 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | 0.4 | 0.3 | 0.5 | 0.3 | 0.3 | 0.2 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 17.9% | 26.3% | 11% | ||||
| Adj EPS ⓘ | NA | 26.2% | 56.9% | 2.7% | ||||
| BVPSⓘ | NA | 23% | 34.5% | 17.2% | ||||
| Share Price | - | - | - | 43.6% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 0 | 0 | 9.6 | 10.6 | 15.4 | 16.9 | 11 | 25.5 | 24.3 | 18.1 | 17.2 |
| Op. Profit Mgn % ⓘ | 0 | 0 | 17.1 | 17.3 | 20.7 | 30 | 27 | 32.3 | 34.6 | 33.7 | 32.9 |
| Net Profit Mgn % ⓘ | 0 | 0 | 9.8 | 9 | 11 | 10.2 | 8 | 15.3 | 18.8 | 17.4 | 16.7 |
| Debt to Equity ⓘ | 0 | 0 | 0.1 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 0 | 0 | 0 | 121 | 78 | 104 | 137 | 86 | 149 | 178 | 78 |
| Cash Conv. Cycle ⓘ | 0 | 0 | 0 | -18 | -7 | -5 | -4 | -9 | -13 | -9 | 60 |
Sales growth is growing at healthy rate in last 3 years 26.25%
Net Profit is growing at healthy rate in last 3 years 56.88%
Sales growth is good in last 4 quarters at 15.39%
Return on Equity has declined versus last 3 years average to 17.20%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 22.4 | 22.8 |
| TTM Sales (₹ Cr.) | 1,366 | 1,425 |
| BVPS (₹.) ⓘ | 134.7 | 132.3 |
| Reserves (₹ Cr.) ⓘ | 1,266 | 1,242 |
| P/BV ⓘ | 11.71 | 11.92 |
| PE ⓘ | 70.35 | 69.18 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1065.05 / 1685.00 |
| All Time Low / High (₹) | 410.00 / 1685.00 |
| Market Cap (₹ Cr.) | 16,015 |
| Equity (₹ Cr.) | 101.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.2 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|
| Sales | 321 | 402 | 543 | 695 | 614 | 925 | 1,114 | 1,237 |
| Operating Expenses ⓘ | 266 | 332 | 430 | 486 | 449 | 626 | 729 | 820 |
| Manufacturing Costs | 29 | 36 | 189 | 236 | 217 | 270 | 362 | 412 |
| Material Costs | 52 | 60 | 80 | 102 | 97 | 188 | 150 | 157 |
| Employee Cost | 69 | 77 | 79 | 102 | 96 | 109 | 136 | 169 |
| Other Costs ⓘ | 116 | 159 | 82 | 46 | 38 | 59 | 80 | 82 |
| Operating Profit ⓘ | 55 | 70 | 112 | 209 | 166 | 299 | 385 | 417 |
| Operating Profit Margin (%) | 17.1% | 17.3% | 20.7% | 30.0% | 27.0% | 32.3% | 34.6% | 33.7% |
| Other Income ⓘ | 11 | 10 | 9 | 12 | 12 | 21 | 31 | 37 |
| Interest ⓘ | 3 | 4 | 6 | 47 | 44 | 53 | 55 | 59 |
| Depreciation ⓘ | 22 | 28 | 36 | 65 | 68 | 77 | 84 | 105 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -5 | 0 |
| Profit Before Tax ⓘ | 41 | 47 | 79 | 109 | 66 | 190 | 273 | 289 |
| Tax ⓘ | 10 | 11 | 20 | 38 | 16 | 47 | 67 | 74 |
| Profit After Tax | 31 | 36 | 60 | 71 | 49 | 142 | 206 | 215 |
| PAT Margin (%) | 9.8% | 9.1% | 11.0% | 10.2% | 8.0% | 15.4% | 18.5% | 17.4% |
| Adjusted EPS (₹) | 3.4 | 4.0 | 6.6 | 7.9 | 5.5 | 15.1 | 20.3 | 21.2 |
| Dividend Payout Ratio (%) | 8% | 12% | 7% | 12% | 0% | 13% | 15% | 14% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 326 | 359 | 414 | 426 | 476 | 636 | 1,088 | 1,276 | ||
| Share Capital ⓘ | 20 | 55 | 55 | 55 | 55 | 105 | 102 | 102 | ||
| Reserves ⓘ | 306 | 304 | 359 | 371 | 421 | 531 | 987 | 1,174 | ||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Debt | 15 | 12 | 50 | 50 | 41 | 27 | 0 | 0 | ||
| Long Term Debt | 10 | 10 | 50 | 46 | 41 | 27 | 0 | 0 | ||
| Short Term Debt | 5 | 2 | 0 | 4 | 0 | 0 | 0 | 0 | ||
| Trade Payables | 20 | 24 | 34 | 42 | 51 | 59 | 75 | 76 | ||
| Others Liabilities ⓘ | 72 | 49 | 58 | 573 | 501 | 551 | 564 | 773 | ||
| Total Liabilities ⓘ | 433 | 445 | 555 | 1,091 | 1,068 | 1,274 | 1,728 | 2,125 | ||
Fixed Assets | ||||||||||
| Gross Block | 192 | 340 | 415 | 809 | 935 | 1,095 | 1,259 | 1,693 | ||
| Accumulated Depreciation | 22 | 48 | 83 | 146 | 213 | 283 | 368 | 474 | ||
| Net Fixed Assetsⓘ | 171 | 293 | 333 | 663 | 722 | 813 | 891 | 1,219 | ||
| CWIP ⓘ | 7 | 12 | 21 | 43 | 29 | 6 | 23 | 20 | ||
| Investmentsⓘ | 6 | 0 | 5 | 24 | 37 | 42 | 105 | 346 | ||
| Inventories | 7 | 6 | 7 | 15 | 9 | 14 | 18 | 23 | ||
| Trade Receivables | 14 | 15 | 29 | 37 | 45 | 41 | 51 | 72 | ||
| Cash Equivalents | 88 | 36 | 69 | 94 | 85 | 175 | 37 | 7 | ||
| Others Assetsⓘ | 140 | 83 | 92 | 216 | 141 | 183 | 603 | 439 | ||
| Total Assets ⓘ | 433 | 445 | 555 | 1,091 | 1,068 | 1,274 | 1,728 | 2,125 | ||
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 36 | 48 | 96 | 178 | 142 | 214 | 316 | 306 |
| PBT ⓘ | 41 | 47 | 79 | 109 | 66 | 190 | 273 | 289 |
| Adjustment ⓘ | 12 | 20 | 32 | 102 | 100 | 110 | 116 | 130 |
| Changes in Working Capital ⓘ | -10 | -6 | -0 | -13 | 2 | -23 | 5 | -27 |
| Tax Paid ⓘ | -8 | -13 | -15 | -20 | -27 | -62 | -78 | -86 |
| Cash Flow From Investing Activity ⓘ | -33 | -42 | -125 | -123 | -87 | -169 | -460 | -214 |
| Capex | -56 | -151 | -80 | -61 | -75 | -58 | -140 | -352 |
| Net Investments | -4 | 5 | -30 | -25 | -18 | -103 | -345 | 94 |
| Others ⓘ | 28 | 103 | -16 | -36 | 7 | -8 | 24 | 45 |
| Cash Flow From Financing Activityⓘ | -1 | -7 | 31 | -54 | -56 | -41 | 148 | -97 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 26 | 266 | 1 |
| Net Proceeds from Borrowing ⓘ | 13 | 1 | 40 | 1 | -5 | -6 | -40 | 0 |
| Interest Paid ⓘ | -1 | -2 | -1 | -5 | -5 | -5 | -3 | 0 |
| Dividend Paid ⓘ | -3 | -3 | -6 | -17 | 0 | -9 | -20 | -30 |
| Others ⓘ | -10 | -3 | -2 | -33 | -46 | -48 | -55 | -68 |
| Net Cash Flow ⓘ | 2 | -2 | 2 | 1 | -2 | 4 | 3 | -4 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 9.96 | 11 | 15.88 | 17.34 | 11.23 | 26.1 | 24.03 | 18.18 | ||
| ROCE (%) | 12.94 | 14.36 | 20.31 | 32.94 | 21.88 | 40.49 | 37.17 | 29.37 | ||
| Asset Turnover Ratio | 0.74 | 0.92 | 1.09 | 0.84 | 0.57 | 0.79 | 0.74 | 0.64 | ||
| PAT to CFO Conversion(x) | 1.16 | 1.33 | 1.6 | 2.51 | 2.9 | 1.51 | 1.53 | 1.42 | Working Capital Days | |
| Receivable Days | 16 | 13 | 15 | 17 | 24 | 17 | 15 | 18 | ||
| Inventory Days | 8 | 6 | 4 | 6 | 7 | 5 | 5 | 6 | ||
| Payable Days | 142 | 135 | 132 | 136 | 175 | 107 | 163 | 176 | ||
The company was originally incorporated as ‘Rainbow Children’s Medicare Private Limited’ under the provisions of the Companies Act, 1956, as a private limited company, at Hyderabad, Telangana, pursuant to a certificate of incorporation dated August 7, 1998, issued by the Registrar of Companies, Hyderabad at Telangana (RoC). Subsequently, the company was converted into a public limited company, and the name of the company was changed to ‘Rainbow Children’s Medicare Limited’ pursuant to a special resolution passed by the Shareholders of the company on November 3, 2021 and a fresh certificate of incorporation was consequently issued by the RoC on November 20, 2021 under the Companies Act, 2013.
Rainbow Children’s Medicare is a leading multi-specialty pediatric and obstetrics and gynecology hospital chain in India. The company’s core specialties are pediatrics, which includes newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care (including multi organ transplants); and obstetrics and gynecology, which includes normal and complex obstetric care, multi-disciplinary fetal care, perinatal genetic and fertility care. The company established its first pediatric specialty hospital in 1999 in Hyderabad, Telangana. Since then, under the leadership of Dr. Ramesh Kancharla, its founding Promoter, it has established its reputation as a leader in multi-specialty pediatric services, with strong clinical expertise in managing complex diseases. It has also expanded its operations to include obstetrics and gynecology services, whereby it offers comprehensive perinatal services to patients.
The company follows a doctor engagement model whereby most of its core specialists work exclusively at its hospitals on a full-time retainer basis. This model ensures that most of its core specialists are available 24/7 on a roster basis at its hospitals, which is particularly important for children’s emergency, neonatal and pediatric intensive care services. The company’s fulltime doctor model along with a strong middle grade doctor pool ensures seamless healthcare delivery across its hospitals, which has resulted in a high degree of patient satisfaction. A number of its doctors in neonatal, pediatric intensive care, pediatric sub specialties, obstetrics and gynecology are trained or possess qualifications from the United Kingdom, United States, Canada and Australia, which provides it with a competitive advantage.
Business area of the company
Rainbow Children's Medicare operates a multi-speciality pediatric, obstetrics and gynaecology hospital chain in India. The company offers a wide range of services such as newborn and pediatric intensive care, pediatric multi-speciality services, pediatric quaternary care, obstetrics and gynaecology, which includes normal and complex obstetric care, and multidisciplinary fetal care, perinatal genetic and fertility care.
Key awards, accreditations or recognitions:
Major events and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
